Skip to main content

Advertisement

You are viewing the new BMC article page. Let us know what you think. Return to old version

Research | Open | Published:

The GC2 haplotype of the vitamin D binding protein is a risk factor for a low plasma 25-hydroxyvitamin D concentration in a Han Chinese population

Abstract

Background

The GC haplotype of the vitamin D binding protein (encoded by the GC gene) might be a risk factor to the vitamin D (VD) nutritional status for many populations, while evidences from the Chinese Han population are sparse. We test the association between vitamin D binding protein genotypes and VD status as well as the metabolic parameters of glucose and lipids in a Han Chinese population.

Methods

In a cross-sectional study conducted at a health examination centre (registered in ClinicalTrials.gov as QLS2013), 2641 adults were included and grouped according to their plasma 25-hydroxyvitamin D (25OHD) concentrations as VD deficient (VDD), insufficient (VDI), or sufficient (VDS). The rs7041 and rs4588 genotypes were analysed with a molecular beacon-based qPCR method using blood samples.

Results

Plasma 25OHD concentrations were lower in the GC2/2, rs7041T/T, and rs4588A/A genotypes than the GC1f/1s, rs7041G/T, and rs4588C/C genotypes (P <  0.05). After adjusting for confounders, the GC2 haplotype increased the risk of low VD status (P <  0.05) in both genders. More genotypic models revealed the negative contributions of rs4588A than rs7041T to low VD status (P <  0.05). The combined rates of VDD and VDI were 80.2% in males and 86.1% in females. Compared with VDI, VDS, or both, VDD showed higher plasma concentrations of fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides in males (P <  0.05); however, no significant differences were found with regard to these parameters between the subgroups defined by the GC genotypes (P > 0.05).

Conclusions

In a Han Chinese population, the GC2 haplotype or more exactly rs4588A is a risk factor for low VD status but is not associated with glucose and lipid metabolic disorders, which are inversely correlated with the circulating 25OHD concentration in males.

Trial registration

The study was retrospectively registered in January 2018 as NCT03406234 in the ClinicalTrials.gov online system.

Background

The high prevalence of vitamin D (VD) malnutrition (deficiency and insufficiency) has been recognized as a global public health problem, even in areas with a significant amount of sunshine [1]. Furthermore, this condition might be related to the high incidences of many chronic diseases, not only that of bone health [2,3,4]. Specifically, the metabolic disorders associated with glucose and lipids might be affected by lower VD nutritional status [5,6,7,8,9,10,11]. These conditions have attracted a growing amount of attention because they are pilot phenotypes for metabolic syndrome, diabetes, dyslipidaemia, and other conditions. The concentration of plasma/serum 25-hydroxyvitamin D (25OHD) is commonly accepted as an indicator of VD nutritional status [2, 12,13,14] .

In the blood stream, the majority of 25OHD and other VD sterols are bound to the VD binding protein (VDBP, encoded by the GC gene) [15,16,17,18], which was initially named as group-specific protein [16]. In healthy people, the circulating VDBP concentration seems to be independent of genetic or racial differences [19], age, adiposity [20], sunshine exposure [21], concentrations of VD sterols, and other hormones [22]; however, both 25OHD and VDBP are predominantly synthesized and secreted by the liver, and their circulating concentrations are impaired by hepatic disease [23, 24]. Moreover, sunshine exposure (including season, latitude, exposure time of the day, and so on), skin colour, VD-rich food, and others affect the circulating concentration of 25OHD. It is also intricately affected by its affinity to VDBP, which is determined by the isoforms of VDBP or the polymorphisms of GC. Of the identified more than 120 single nucleotide polymorphisms (SNPs), rs7041 and rs4588 are the most commonly concerned because they are missense SNPs located on the 11th exon of GC. Rs7041T  > G encodes aspartic acid  > glutamic acid, and rs4588C > A encodes threonine > lysine. Combined with the alleles of the two SNPs in complete linkage disequilibrium [25], GC has three high-frequency allelic variants. The most frequent variant is designated as GC1f (rs7041T-rs4588C); rs7041G defines the GC1s form (rs7041G-rs4588C), and rs4588A defines GC2 (rs7041T-rs4588A) [26]. Thus, the GC gene has 6 genotypes: 1f/1f, 1s/1s, 1f/1s, 2/2, 1f/2, and 1s/2. If GC1f and GC1s are combined, then GC1/1 is equal to rs4588C/C, GC1/2 is equal to rs4588C/A, and GC2/2 is equal to rs4588A/A in genotypic frequencies.

Although studies have suggested that the GC2 haplotype has lower circulating concentrations of VDBP and 25OHD in certain races or populations [27,28,29], others have challenged these findings by not finding the affinity difference [30, 31] or even the opposite relationship [32]. The present study analyses the effect of the GC genotype on the plasma 25OHD concentration in a Han Chinese population living in South China, illuminates the concern about the genotypes of GC when using 25OHD to evaluate the VD status, and explores the association between GC genotypes and specific phenotypes associated with VD deficiency.

Methods

Participants and sample collection

This study was approved by the Ethic Committee of Shenzhen Centre of Chronic Disease Control and had the registration ID of NCT03406234 in the ClinicalTrials.gov online system. Participants, randomly recruited over one year at a health examination centre in Shenzhen City, were informed of the purpose of the questionnaire, physical examination, and blood sampling, and they provided their written consent. Health history and food intake data were collected via face-to-face interviews using a computerized version of the questionnaire applied in China’s 2010 Chronic Disease and Risk Factor Surveillance [33], into which questions regarding sunshine exposure and sun protection use (collected by 3 categorized values: 1 = never use; 2 = use always under sunshine; and 3 = use only under strong sunlight) were incorporated. VD intakes were calculated using the dietary VD concentration data published by the US Department of Agriculture (USDA Nutrient Database for Standard Reference, Release 28. Nutrient Data Laboratory Home Page, 2018) and the VD supplement dosage if VD supplementations were used by some participants.

The inclusion criteria for the participants were ≥ 18 years old, member of the Han population, living in Shenzhen for > 2 years, not pregnant, and free of hepatic and renal disease. Participants were grouped as being VD deficient (VDD), VD insufficient (VDI), or VD sufficient (VDS) with plasma 25OHD concentrations of < 50, 50 - < 75, or ≥ 75 nmol/L, respectively [2, 13, 14, 34].

Overnight (> 10 h) fasting blood samples were drawn from the ulnar vein and collected with a 10-mL EDTA-K2 anticoagulate tube (Cat. #: 366643, BD Company). Concentrations of red blood cells and haemoglobin were determined with whole blood samples. The samples of plasma and blood cells were prepared via centrifugation at 4 °C 3000×g for 10 min.

Biochemical assays

The concentrations of fasting plasma glucose (FPG), high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), total cholesterol, and triglycerides in fresh plasma were determined with a Beckman-LX20 automatic analyser. Red blood cells and haemoglobin were analysed with an XS-800i haematology analyser (Sysmex Corporation, Shanghai, China). A plasma concentration of 25OHD was analysed with the enzyme-linked immunosorbent assay (ELISA) method (Cat. #: AC-57F1, IDS Ltd., UK) validated by the Vitamin D External Quality Assessment Scheme as previously described [34, 35]. The VDBP concentration was measured using a commercial ELISA kit (Cat. #: LE-H5018, Lai Er Bio-Tech, Hefei, China) on a Multiskan Go microplate reader (Thermo-Fisher Scientific Inc.).

Genotype analysis

DNA samples were prepared from the blood cells with a commercial kit (Cat. #: D3392–02, Omega Bio-tek) for genotyping using the molecular beacon method on a Roche 480II qPCR validated by sequencing (Thermo-Fisher, Shanghai, China). Briefly, a pair of primers and a molecular beacon probe were designed to determine the genotypes of the two adjacent SNPs of rs7041 and rs4588, and the asymmetric qPCR program was established for a melting curve analysis [36]. The forward primer sequence was 5’-GGTTTTTCAGACTGGCAGAGCGACTA-3′, the backward primer sequence was 5’-GAGGTGAGTTTATGGAACAGCA-3′, and the molecular beacon probe was 5′-fluorophore-cacagCTGATGCCACACCCAAGGAACTGtg-quencher-3′ (bold underlined bases were the alleles for rs7041 and rs4588, respectively). The genotypes were determined using the different melting curves (Additional file 1: Figure S1).

Statistical analyses

A one-way ANOVA followed by Bonferroni test was performed for the numerical parameters, and χ2-tests were performed for the percentage or frequency data using SPSS19.0 (IBM). The genotypic frequencies across participants was examined using the Hardy-Weinberg equilibrium (HWE) for sampling representativeness. The contribution of different genotypes to VD status were analysed with logistic regressions. Differences with statistical probabilities less than 0.05 (P <  0.05) were accepted as significant.

Results

The clinical profiles and biochemical measures of participants

A total of 2641 participants (1119 males and 1522 females) were included in this study. The clinical profiles are summarized in Table 1. More than half of the participants showed a VDI status, (i.e., 61.4% of males and 58.0% of females), and the combined rates of VDD and VDI were 80.2% in males and 86.1% in females. The rate of VD supplementation use (primarily fish oil) was less than 10%, and the VD supplement dosages for those participants were included for total VD intake adjustment in the logistic analysis. No participant showed a potentially toxic VD status (plasma 25OHD > 250 nmol/L), and the highest level was 165 nmol/L.

Table 1 Clinic profiles of subjects at vitamin D (VD) deficient (VDD), VD insufficient (VDI), and VD sufficient (VDS) statuses 1

The self-reported mean times of sunshine exposure were 34.7–41.5 min for males and 30.9–33.5 min for females per day. Between different VD statuses, sunshine exposure time did not differ in both (P = 0.09) or either of the genders (P = 0.25 for males and 0.63 for females, Table 1), while males had higher sunshine exposure time than females in total (P <  0.001), VDI (P <  0.001), or VDS status (P = 0.04). The percentages of never using sun protection was 84% in males and 18.3% in females. The means of the total VD intakes were 129–136 IU/d for males and 119–127 IU/d for females, and these values did not significantly differ across the VD statuses of either gender (P = 0.51 for males and 0.31 for females). Males had higher total VD intakes (P = 0.001). No significant differences were found with regard to the VD intakes from staple food, egg and milk, and mushroom between the VD statuses of either gender; however, VDD females showed significant lower VD intakes from meat and fish than VDI females (P = 0.005). The mean plasma VDBP concentration was approximately 240 mg/L and did not differ across the VD nutritional subgroups (P = 0.91 for males and 0.75 for females, Table 1) or the GC genotypes (P = 0.45 for males and 0.11 for females, Additional file 1: Table S1).

In males, the circulating concentrations of FPG, HDLC, LDLC, and triglycerides were higher in group(s) with lower VD nutritional statuses than the group(s) with higher VD nutritional status (P <  0.05). In female participants, however, no differences were found in the assayed biochemical parameters amongst the VD groups, and a higher VD status was associated with an older age (P <  0.001). VDD females also had lower body mass indices (BMIs) than those with a higher VD status (P = 0.02, Table 1). When the FPG and lipid profiles of males were compared between the subgroups divided by the genotypes of rs4588, no significant differences were identified (P > 0.05, Additional file 1: Table S2).

In the partial correlation analyses between the plasma 25OHD concentration and its affecting factors, 25OHD was not significantly correlated with BMI (P = 0.14), sunshine exposure time (P = 0.09), or the plasma VDBP concentration (P = 0.39); however, it was positively correlated with age (P <  0.01, Additional file 1: Table S3).

Genotypes of GC and its effect on VD status

Both of the minor allele frequencies (MAFs) of rs7041G and rs4588A were 0.289 in the total population. The genotypic and allelic frequencies of rs7041-rs4588, rs7041, and rs4588 are summarized in Table 2. Except for the genotypic frequency of rs7041 in males, all of the frequencies in both males and females differed across VD statuses (P <  0.05). The allelic frequency rank of rs7041G was VDD < VDI < VDS, whereas that of rs4588A was reversed in both males and females. Figure 1 compares the plasma 25OHD concentrations in the subgroups of different genotypes. In both genders, 1f/1s showed significantly higher plasma 25OHD concentrations than all three rs7041T-rs4588A (GC2) haplotype carriers (GC2/2, GC1f/2, and GC1s/2. P = 0.001, 0.008, and 0.026 respectively for males and <  0.001, 0.002, and 0.011 respectively for females). Significantly lower plasma 25OHD concentrations were observed in the rs7041T/T homozygotes than the rs7041G/T heterozygotes (P = 0.016 for males and 0.009 for females) but not the rs7041G/G homozygotes (P = 0.08 for males and 0.53 for females). Conversely, the rs4588A/A homozygotes had lower plasma 25OHD concentrations than the rs4588C/C homozygotes (P = 0.002 for males and < 0.001 for females).

Table 2 Univariate analyses of the genotypic or allelic frequencies of rs7041 and rs4588 in vitamin D binding protein gene1
Fig. 1
figure1

Plasma 25OHD concentrations in males and females with genotypes of rs7041-rs4588 (a), rs7041 (b), and rs4588 (c) in vitamin D binding protein gene. Data are means ± SD, and differ without a common letter, P < 0.05. For the 6 genotypes of 1f/1f, 1s/1s, 1f/1s, 2/2, 1f/2, and 1s/2, n = 212, 98, 261, 88, 278, and 182 in males and 253, 116, 405, 140, 356, and 252 in females, respectively. For the G/G, G/T, and T/T genotypes of rs7041, n = 98, 443, and 578 in males and 116, 657, and 749 in females, respectively. For the A/A, A/C, and C/C genotypes of rs4588 (or GC2/2, GC1/2, and GC1/1 of VDBP), n = 88, 460, and 571 in males and 140, 608, and 774 in females, respectively

Logistic analyses were performed to compare the contribution of the different GC genotypes to VD status after adjusting for (gender,) age, BMI, sampling month, smoking status, sunshine exposure, sun protection use, and total VD intakes. Figures 2, 3 and 4 were created using the odds ratio (OR) and 95% confidential interval (CI) data. Taking the 1f/1s genotype as the reference, 2/2, 1f/2, and/or 1s/2 significantly decreased the possibility of higher VD status (P < 0.05). Namely, it increased the risk of lower VD status. Furthermore, when the two SNPs were separately examined with additive, dominant, recessive, homozygous, and allelic models, a negative contribution was more frequently found for rs4588 than rs7041 when comparing the higher with the lower statuses (i.e., VDI vs VDD, VDS vs VDD, or VDS vs VDI, P < 0.05), especially amongst females.

Fig. 2
figure2

Logistic analysis on the contribution of vitamin D binding protein genotypes (1f/1f, 1 s/1 s, 2/2, 1f/2, or 1 s/2 against 1f/1 s) to the vitamin D (VD) statuses after adjusting for (gender,) age, body mass index, sampling month, smoking status, sunshine exposure time, sun protection use, and total vitamin D intakes. a, d, and g are VD insufficient (VDI) vs VD deficient (VDD), b, e, and h are VD sufficient (VDS) vs VDD, and c, f, and i are VDS vs VDI in both genders, male, and female, respectively. Data are odds ratio (OR, represented by , , , and▲) ± 95% of confidential interval (CI). , P ≥ 0.1; , 0.05 ≤ P < 0.1; , 0.01 ≤ P < 0.05; ▲, P < 0.01

Fig. 3
figure3

Logistic analysis on the contribution of rs7041 in different genotypic models to the vitamin D (VD) statuses after adjusting for (gender,) age, body mass index, sampling month, smoking status, sunshine exposure time, sun protection use, and total vitamin D intakes. a, d, and g are VD insufficient (VDI) vs VD deficient (VDD), b, e, and h are VD sufficient (VDS) vs VDD, and c, f, and i are VDS vs VDI in both genders, male, and female, respectively. Data are odds ratio (OR, represented by , , , and▲) ± 95% of confidential interval (CI). , P ≥ 0.1; , 0.05 ≤ P < 0.1; , 0.01 ≤ P < 0.05; ▲, P < 0.01. Add., additive model; Alle., allelic model; Dom., dominant model; Hom., homozygous model; Rec., recessive model

Fig. 4
figure4

Logistic analysis on the contribution of rs4588 in different genotypic models to the vitamin D (VD) statuses after adjusting for (gender,) age, body mass index, sampling month, smoking status, sunshine exposure time, sun protection use, and total vitamin D intakes. a, d, and g are VD insufficient (VDI) vs VD deficient (VDD), b, e, and h are VD sufficient (VDS) vs VDD, and c, f, and i are VDS vs VDI in both genders, male, and female, respectively. Data are odds ratio (OR, represented by , , , and▲) ± 95% of confidential interval (CI). , P ≥ 0.1; , 0.05 ≤ P < 0.1; , 0.01 ≤ P < 0.05; ▲, P < 0.01. Add., additive model; Alle., allelic model; Dom., dominant model; Hom., homozygous model; Rec., recessive model

Discussion

The effect of VDBP on the 25OHD concentration

No differences in the VDBP concentrations were found using polyclonal antibody method [37] or the LC-MS/MS method [19, 38], though the ELISA method with a monoclonal antibody for VDBP may induce bias [38,39,40,41,42]. Using an ELISA kit with a polyclonal antibody, we did not find a difference in the plasma VDBP concentrations between the subgroups of participants (Table 1 and Additional file 1: Table S1), nor was the VDBP concentration correlated with the plasma 25OHD concentration (Additional file 1: Table S3).

Although the varied 25OHD concentrations might not result from the constant concentration of VDBP in healthy people [20, 43], the missense variations in rs7041 and rs4588 might affect the affinity of VDBP to VD sterols. The rs4588A base pair leading to the lysine amino acid in the GC2 protein lacked the preferred site of O-linked glycosylation, which might reduce the affinity of VDBP to VD sterols, and result in a lower 25OHD concentration in many populations [28, 40, 44,45,46,47,48,49,50,51,52,53,54,55]. While rs7041 was tightly linked with rs4588 on the same exon, and thus both of the two SNPs are associated with 25OHD concentrations [56]. An additional copy of rs7041T or rs4588A was associated with lower 25OHD concentrations in premenopausal white women [57]. Rs7041T/T, rs4588A/A, GC1f/2, and GC2/2 were associated with lower 25OHD levels in a cross-sectional survey of healthy girls from southern Brazil [58]. In a rural region of the Gambia in western Africa, the plasma 25OHD concentration was higher in homozygotes for GC1f compared with other GC variants [59]. Lin’s group also found that rs4588A and rs7041T had lower plasma 25OHD concentration in adult Chinese Hans living in high (Beijing) and mid (Shanghai) latitude cities [60]; and further, rs4588C had higher 25OHD increase by oral VD supplementation [61]. However, an inconsistency was observe in certain studies [28, 32, 49, 51, 54], which might be explained by the fact that rs7041T exists in both GC1f and GC2, which have the highest and lowest affinities to 25OHD, respectively [46], and presented a splitting effect between the two opposite phenotypes in certain instances. Moreover, a recent study found that a lower 25OHD level was associated with rs7041T/T but not with the genotypes of rs4588 [62].

Consistent with most findings, GC2/2 had the lowest VD status in both male and female Han Chinese adults of the present study, and GC2 carriers (GC2/2, GC1f/2, and GC1s/2) had lower 25OHD values than GC1f/1s individuals, though they resided in much lower latitude. The plasma 25OHD concentration (nmol/L) means were 64.9, 61.8, and 58.9 in males and 61.0, 57.6, and 54.0 in females for the GC1/1 (rs4588C/C), GC1/2 (rs4588C/A), and GC2/2 (rs4588A/A) genotypes, respectively. It highly suggested a dose-response relationship between the GC2 haplotype (or rs4588A) copies and low VD status. The rs7041T/T subgroup showed a lower 25OHD than the rs7041G/T but not the rs7041G/G subgroup, having no suggestion for a dose-response relationship. The negative association of GC2 haplotype with VD status was confirmed by logistic regression analysis, and rs4588A was more precise or sensitive than rs7041T to predict the risk of low VD nutritional status in both or either gender(s).

Other factors influencing VD status

Excluding the contribution of genetic differences, the 25OHD levels in individuals not taking supplements largely depend on sunshine exposure, diet [52, 63], and indirect factors that affect the bioavailability or synthesis of VD such as age, BMI, gender, and so on. Although the sunshine exposure means amongst our male participants seemed to increase with VD status (Table 1), the great variation in this sample did not support a significant difference, and this result was not correlated with plasma 25OHD concertation (Additional file 1: Table S3). This explanation might be a limitation of the method used to collect sunshine exposure data. Similarly, dietary VD intakes also seemed to have limited effects on the VD status amongst the subgroups. The lower VD intakes from meat and fish in VDD females suggest an intentional bias in food choice to keep slim, whereas VDS females might be more likely to benefit from the VD supplements consumption.

The overall concentration of plasma 25OHD in females was much lower than that in males (P < 0.001), and the means of age increased with VD status in females (P < 0.001, Table 1). These findings are consistent with those of previous studies [64,65,66]. These effects might be explained by less outdoor activity of labour ages and sunshade habits including the use of sunscreen, sun hats, and parasols, especially amongst young women [57, 65].

Because VD sterols are fat soluble, obesity might reduce the circulating 25OHD concentration, and negative associations between BMI and 25OHD have been reported by many studies [67, 68]. In certain situations [35, 67, 69, 70], including a Chinese national report [66] and the present study, however, a null association has been found between these two parameters, most likely because BMI is not a perfect marker for obesity, especially the lower BMI range with regard to the Han Chinese population.

VD nutritional status and biochemical profiles

Lower VD status was coupled with higher FPG, HDLC, LDLC, and triglyceride levels in the current male participants (Table 1) as well as coupled with an increasing number of rs4588A genotypes (Additional file 1: Table S2). However, the FPG and lipid levels did not differ across the rs4588 genotypes. Thus, VD status and not the genetic variations of VDBP were associated with these parameters in males.

To explore the cause and effect between VD status and ill health, a recent meta-analysis confirmed the moderate-to-strong inverse associations between 25OHD concentrations and various outcomes of observational studies, including serum lipid concentrations and glucose metabolism disorders [3]. However, the results from intervention studies have not supported the benefit of VD supplementation to reverse these disorders [3], which implies that low 25OHD is a marker of ill health and not the cause. If so, then our data suggest that males are more likely to have glucose and lipid metabolic disorders to affect their VD status than females.

Limitations

In the present study, the sample size of the populations was moderate, and the measured 25OHD concentration was for the total instead of free and bioavailable fractions, which were suggested to be more accurate for revealing the relevance of 25OHD with the health outcomes [15, 71, 72]. These limitations might lead to the null associations of circulating 25OHD concentration with FPG and lipid profiles.

Conclusions

The GC2 haplotype of VDBP is a risk factor for a lower circulating 25OHD concentration in an adult Han population in southern China, and rs4588 was more sensitive than rs7041 to predict the VD status. However, the GC2 haplotype was not related to FPG, HDLC, LDLC, or triglyceride levels in either gender, though these glucose/lipid profiles were higher in males with lower VD status.

Abbreviations

25OHD:

25-hydroxyvitamin D

BMI:

Body mass index

CI:

Confidential interval

DBP:

Diastolic blood pressure

ELISA:

Enzyme-linked immunosorbent assay

FPG:

Fasting plasma glucose

HDLC:

High-density lipoprotein cholesterol

HWE:

Hardy-Weinberg equilibrium

LDLC:

Low-density lipoprotein cholesterol

MAF:

Minor allele frequency

OR:

Odds ratio

SBP:

Systolic blood pressure

VD:

Vitamin D

VDBP:

VD binding protein

VDD:

VD deficient

VDI:

VD insufficient

VDS:

VD sufficient

References

  1. 1.

    Manios Y, Moschonis G, Lambrinou CP, Tsoutsoulopoulou K, Binou P, Karachaliou A, et al. A systematic review of vitamin D status in southern European countries. Eur J Nutr. 2018;57:2001–36. https://doi.org/10.1007/s00394-017-1564-2.

  2. 2.

    Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18:153–65. https://doi.org/10.1007/s11154-017-9424-1.

  3. 3.

    Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2:76–89. https://doi.org/10.1016/S2213-8587(13)70165-7.

  4. 4.

    Battault S, Whiting SJ, Peltier SL, Sadrin S, Gerber G, Maixent JM. Vitamin D metabolism, functions and needs: from science to health claims. Eur J Nutr. 2013;52:429–41. https://doi.org/10.1007/s00394-012-0430-5.

  5. 5.

    Huang CY, Chang HH, Lu CW, Tseng FY, Lee LT, Huang KC. Vitamin D status and risk of metabolic syndrome among non-diabetic young adults. Clin Nutr. 2015;34:484–9. https://doi.org/10.1016/j.clnu.2014.05.010.

  6. 6.

    Schmitt EB, Nahas-Neto J, Bueloni-Dias F, Poloni PF, Orsatti CL, Petri Nahas EA. Vitamin D deficiency is associated with metabolic syndrome in postmenopausal women. Maturitas. 2018;107:97–102. https://doi.org/10.1016/j.maturitas.2017.10.011.

  7. 7.

    Kim YS, Hwang JH, Song MR. The association between vitamin D deficiency and metabolic syndrome in Korean adolescents. J Pediatr Nurs. 2018;38:e7–11. https://doi.org/10.1016/j.pedn.2017.11.005.

  8. 8.

    Bonakdaran S, Fakhraee F, Karimian MS, Mirhafez SR, Rokni H, Mohebati M, et al. Association between serum 25-hydroxyvitamin D concentrations and prevalence of metabolic syndrome. Adv Med Sci. 2016;61:219–23. https://doi.org/10.1016/j.advms.2016.01.002.

  9. 9.

    Barbalho SM, Tofano RJ, De Campos AL, Rodrigues AS, Quesada K, Bechara MD, et al. Association between vitamin D status and metabolic syndrome risk factors. Diabetes Metab Syndr. 2018;12:501–7.

  10. 10.

    Mansouri M, Abasi R, Nasiri M, Sharifi F, Vesaly S, Sadeghi O, et al. Association of vitamin D status with metabolic syndrome and its components: A cross-sectional study in a population of high educated Iranian adults. Diabetes Metab Syndr. 2018;12:393–8.

  11. 11.

    Koziarska-Rościszewska M, Rysz J, Stępień M. High prevalence of vitamin D deficiency and its association with metabolic disorders in elderly patients. Fam Med Prim Care Rev. 2017;19:372–6.

  12. 12.

    Heaney RP. Serum 25-hydroxyvitamin D is a reliable indicator of vitamin D status. Am J Clin Nutr. 2011;94:619–20. https://doi.org/10.3945/ajcn.111.019539.

  13. 13.

    Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998;351:805–6.

  14. 14.

    Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009;205:255–60. doi: S0021–9150(08)00773–9 https://doi.org/10.1016/j.atherosclerosis.2008.10.033.

  15. 15.

    Jassil NK, Sharma A, Bikle D, Wang X. Vitamin D binding protein and 25-Hydroxyvitamin D levels: emerging clinical applications. Endocr Pract. 2017;23:605–13. https://doi.org/10.4158/EP161604.RA.

  16. 16.

    Cooke NE, David EV. Serum vitamin D-binding protein is a third member of the albumin and alpha fetoprotein gene family. J Clin Invest. 1985;76:2420–4. https://doi.org/10.1172/JCI112256.

  17. 17.

    Kida K, Goodman DS. Studies on the transport of vitamin D and of 25-hydroxyvitamin D in human plasma. J Lipid Res. 1976;17:485–90.

  18. 18.

    Imawari M, Kida K, Goodman DS. The transport of vitamin D and its 25-hydroxy metabolite in human plasma. Isolation and partial characterization of vitamin D and 25-hydroxyvitamin D binding protein. J Clin Invest. 1976;58:514–23. https://doi.org/10.1172/JCI108495.

  19. 19.

    Henderson CM, Lutsey PL, Misialek JR, Laha TJ, Selvin E, Eckfeldt JH, et al. Measurement by a novel LC-MS/MS methodology reveals similar serum concentrations of Vitamin D-binding protein in blacks and whites. Clin Chem. 2016;62:179–87. https://doi.org/10.1373/clinchem.2015.244541.

  20. 20.

    Bolland MJ, Grey AB, Ames RW, Horne AM, Mason BH, Wattie DJ, et al. Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. Clin Endocrinol. 2007;67:259–64. https://doi.org/10.1111/j.1365-2265.2007.02873.x.

  21. 21.

    Goswami R, Saha S, Sreenivas V, Singh N, Lakshmy R. Vitamin D-binding protein, vitamin D status and serum bioavailable 25(OH)D of young Asian Indian males working in outdoor and indoor environments. J Bone Miner Metab. 2017;35:177–84. https://doi.org/10.1007/s00774-016-0739-x.

  22. 22.

    Cooke NE, Haddad JG. Vitamin D binding protein (Gc-globulin). Endocr Rev. 1989;10:294–307. https://doi.org/10.1210/edrv-10-3-294.

  23. 23.

    Bikle DD, Halloran BP, Gee E, Ryzen E, Haddad JG. Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels. J Clin Invest. 1986;78:748–52.

  24. 24.

    Ko BJ, Kim YS, Kim SG, Park JH, Lee SH, Jeong SW, et al. Relationship between 25-hydroxyvitamin D levels and liver fibrosis as assessed by transient elastography in patients with chronic liver disease. Gut Liver. 2016;10:818–25.

  25. 25.

    Cleve H, Constans J. The mutants of the vitamin-D-binding protein: more than 120 variants of the GC/DBP system. Vox Sang. 1988;54:215–25.

  26. 26.

    Borges CR, Rehder DS, Jarvis JW, Schaab MR, Oran PE, Nelson RW. Full-length characterization of proteins in human populations. Clin Chem. 2010;56:202–11. https://doi.org/10.1373/clinchem.2009.134858.

  27. 27.

    Yousefzadeh P, Shapses SA, Wang X, Vitamin D. Binding protein impact on 25-Hydroxyvitamin D levels under different physiologic and pathologic conditions. Int J Endocrinol. 2014;2014:981581. https://doi.org/10.1155/2014/981581.

  28. 28.

    Lauridsen AL, Vestergaard P, Hermann AP, Brot C, Heickendorff L, Mosekilde L, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int. 2005;77:15–22. https://doi.org/10.1007/s00223-004-0227-5.

  29. 29.

    Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomark Prev. 2008;17:1339–43. https://doi.org/10.1158/1055-9965.EPI-08-0162.

  30. 30.

    Bouillon R, van Baelen H, de Moor P. Comparative study of the affinity of the serum vitamin D-binding protein. J Steroid Biochem. 1980;13:1029–34.

  31. 31.

    Boutin B, Galbraith RM, Arnaud P. Comparative affinity of the major genetic variants of human group-specific component (vitamin D-binding protein) for 25-(OH) vitamin D. J Steroid Biochem. 1989;32:59–63.

  32. 32.

    Almesri N, Das NS, Ali ME, Gumaa K, Giha HA. Independent associations of polymorphisms in vitamin D binding protein (GC) and vitamin D receptor (VDR) genes with obesity and plasma 25OHD3 levels demonstrate sex dimorphism. Appl Physiol Nutr Metab. 2016;41:345–53. https://doi.org/10.1139/apnm-2015-0284.

  33. 33.

    Zhou JC, Zheng S, Mo J, Liang X, Xu Y, Zhang H, et al. Dietary selenium deficiency or excess reduces sperm quality and testicular mRNA abundance of nuclear glutathione peroxidase 4 in rats. J Nutr. 2017;147:1947–53. https://doi.org/10.3945/jn.117.252544.

  34. 34.

    Zhou JC, Zhu YM, Chen Z, Mo JL, Xie FZ, Wen YH, et al. Oral vitamin D supplementation has a lower bioavailability and reduces hypersecretion of parathyroid hormone and insulin resistance in obese Chinese males. Public Health Nutr. 2015;18:2211–9. https://doi.org/10.1017/S1368980014002845.

  35. 35.

    Zhou JC, Zhu YM, Guo P, Chen Z, Xie FZ, Liu XL, et al. Serum 25(OH)D and lipid levels in Chinese obese and normal weight males before and after oral vitamin D supplementation. Biomed Environ Sci. 2013;26:801–7. https://doi.org/10.3967/bes2013.003.

  36. 36.

    Vet JA, Marras SA. Design and optimization of molecular beacon real-time polymerase chain reaction assays. Methods Mol Biol. 2005;288:273–90.

  37. 37.

    Bouillon R, Jones K, Schoenmakers I. Vitamin D-binding protein and vitamin D in blacks and whites. N Engl J Med. 2014;370:879. https://doi.org/10.1056/NEJMc1315850#SA3.

  38. 38.

    Hoofnagle AN, Eckfeldt JH, Lutsey PL. Vitamin D-binding protein concentrations quantified by mass spectrometry. N Engl J Med. 2015;373:1480–2. https://doi.org/10.1056/NEJMc1502602.

  39. 39.

    Powe CE, Karumanchi SA, Thadhani R. Vitamin D-binding protein and vitamin D in blacks and whites. N Engl J Med. 2014;370:880–1. https://doi.org/10.1056/NEJMc1315850.

  40. 40.

    Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369:1991–2000. https://doi.org/10.1056/NEJMoa1306357.

  41. 41.

    Hollis BW, Bikle DD. Vitamin D-binding protein and vitamin D in blacks and whites. N Engl J Med. 2014;370:879–80. https://doi.org/10.1056/NEJMc1315850#SA4.

  42. 42.

    Medlej-Hashim M, Jounblat R, Hamade A, Ibrahim JN, Rizk F, Azzi G, et al. Hypovitaminosis D in a young Lebanese population: effect of GC gene polymorphisms on Vitamin D and Vitamin D binding protein levels. Ann Hum Genet. 2015;79:394–401. https://doi.org/10.1111/ahg.12133.

  43. 43.

    Bouillon R, Van Assche FA, Van Baelen H, Heyns W, De Moor P. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. J Clin Invest. 1981;67:589–96. https://doi.org/10.1172/JCI110072.

  44. 44.

    Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta. 2006;372:33–42. https://doi.org/10.1016/j.cca.2006.03.011.

  45. 45.

    Borges CR, Jarvis JW, Oran PE, Nelson RW. Population studies of Vitamin D binding protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent O-glycosylation patterns. J Proteome Res. 2008;7:4143–53. https://doi.org/10.1021/pr8002936.

  46. 46.

    Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet. 1993;92:183–8.

  47. 47.

    Constans J, Viau M, Bouissou C. Affinity differences for the 25-OH-D3 associated with the genetic heterogeneity of the vitamin D-binding protein. FEBS Lett. 1980;111:107–11.

  48. 48.

    Engelman CD, Fingerlin TE, Langefeld CD, Hicks PJ, Rich SS, Wagenknecht LE, et al. Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels in Hispanic and African Americans. J Clin Endocrinol Metab. 2008;93:3381–8. https://doi.org/10.1210/jc.2007-2702.

  49. 49.

    Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves' disease and the vitamin D status in a polish population study. Exp Clin Endocrinol Diabetes. 2006;114:329–35. https://doi.org/10.1055/s-2006-924256.

  50. 50.

    Braun A, Bichlmaier R, Cleve H. Molecular analysis of the gene for the human vitamin-D-binding protein (group-specific component): allelic differences of the common genetic GC types. Hum Genet. 1992;89:401–6.

  51. 51.

    Maneechay W, Boonpipattanapong T, Kanngurn S, Puttawibul P, Geater SL, Sangkhathat S. Single nucleotide polymorphisms in the Gc gene for vitamin D binding protein in common cancers in Thailand. Asian Pac J Cancer Prev. 2015;16:3339–44.

  52. 52.

    Fu L, Yun F, Oczak M, Wong BY, Vieth R, Cole DE. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem. 2009;42:1174–7. https://doi.org/10.1016/j.clinbiochem.2009.03.008.

  53. 53.

    Michos ED, Misialek JR, Selvin E, Folsom AR, Pankow JS, Post WS, et al. 25-hydroxyvitamin D levels, vitamin D binding protein gene polymorphisms and incident coronary heart disease among whites and blacks: the ARIC study. Atherosclerosis. 2015;241:12–7. https://doi.org/10.1016/j.atherosclerosis.2015.04.803.

  54. 54.

    Gozdzik A, Zhu J, Wong BY, Fu L, Cole DE, Parra EJ. Association of vitamin D binding protein (VDBP) polymorphisms and serum 25(OH)D concentrations in a sample of young Canadian adults of different ancestry. J Steroid Biochem Mol Biol. 2011;127:405–12. https://doi.org/10.1016/j.jsbmb.2011.05.009.

  55. 55.

    Pekkinen M, Saarnio E, Viljakainen HT, Kokkonen E, Jakobsen J, Cashman K, et al. Vitamin D binding protein genotype is associated with serum 25-hydroxyvitamin D and PTH concentrations, as well as bone health in children and adolescents in Finland. PLoS One. 2014;9:e87292. https://doi.org/10.1371/journal.pone.0087292.

  56. 56.

    Chun SK, Shin S, Kim MY, Joung H, Chung J. Effects of maternal genetic polymorphisms in vitamin D-binding protein and serum 25-hydroxyvitamin D concentration on infant birth weight. Nutrition. 2017;35:36–42. https://doi.org/10.1016/j.nut.2016.10.006.

  57. 57.

    Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr. 2009;89:634–40. https://doi.org/10.3945/ajcn.2008.26445.

  58. 58.

    Santos BR, Mascarenhas LP, Boguszewski MC, Spritzer PM. Variations in the vitamin D-binding protein (DBP) gene are related to lower 25-hydroxyvitamin D levels in healthy girls: a cross-sectional study. Horm Res Paediatr. 2013;79:162–8. https://doi.org/10.1159/000348847.

  59. 59.

    Braithwaite VS, Jones KS, Schoenmakers I, Silver M, Prentice A, Hennig BJ. Vitamin D binding protein genotype is associated with plasma 25OHD concentration in west African children. Bone. 2015;74:166–70. https://doi.org/10.1016/j.bone.2014.12.068.

  60. 60.

    Lu L, Sheng H, Li H, Gan W, Liu C, Zhu J, et al. Associations between common variants in GC and DHCR7/NADSYN1 and vitamin D concentration in Chinese Hans. Hum Genet. 2012;131:505–12. https://doi.org/10.1007/s00439-011-1099-1.

  61. 61.

    Yao P, Sun L, Lu L, Ding H, Chen X, Tang L, et al. Effects of Genetic and Nongenetic Factors on Total and Bioavailable 25(OH)D Responses to Vitamin D Supplementation. J Clin Endocrinol Metab. 2017;102:100–10. https://doi.org/10.1210/jc.2016-2930.

  62. 62.

    Santos BR, Lecke SB, Spritzer PM. Genetic variant in vitamin D-binding protein is associated with metabolic syndrome and lower 25-hydroxyvitamin D levels in polycystic ovary syndrome: a cross-sectional study. PLoS One. 2017;12:e0173695. https://doi.org/10.1371/journal.pone.0173695.

  63. 63.

    Calvo MS, Whiting SJ. Overview of the proceedings from experimental biology 2004 symposium: vitamin D insufficiency: a significant risk factor in chronic diseases and potential disease-specific biomarkers of vitamin D sufficiency. J Nutr. 2005;135:301–3.

  64. 64.

    Zhu Y, Chen Z, Zhou JC, Liu X, Guo P, Wen Y. Preliminary study on vitamin D nutritional status in indoor staff with normal body mass index in subtropical China. Mod Prev Med. 2014;41:19–21. (in Chinese).

  65. 65.

    Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20:1807–20. https://doi.org/10.1007/s00198-009-0954-6.

  66. 66.

    Chen J, Yun C, He Y, Piao J, Yang L, Yang X. Vitamin D status among the elderly Chinese population: a cross-sectional analysis of the 2010-2013 China national nutrition and health survey (CNNHS). Nutr J. 2017;16:3. https://doi.org/10.1186/s12937-016-0224-3.

  67. 67.

    Saneei P, Salehi-Abargouei A, Esmaillzadeh A. Serum 25-hydroxy vitamin D levels in relation to body mass index: a systematic review and meta-analysis. Obes Rev. 2013;14:393–404. https://doi.org/10.1111/obr.12016.

  68. 68.

    Konradsen S, Ag H, Lindberg F, Hexeberg S, Jorde R. Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. Eur J Nutr. 2008;47:87–91. https://doi.org/10.1007/s00394-008-0700-4.

  69. 69.

    Dix CF, Bauer JD, Martin I, Rochester S, Duarte Romero B, Prins JB, et al. Association of sun exposure, skin colour and body mass index with vitamin D status in individuals who are morbidly obese. Nutrients. 2017;9:1094. https://doi.org/10.3390/nu9101094.

  70. 70.

    Baradaran A, Behradmanesh S, Nasri H. Association of body mass index and serum vitamin D level in healthy Iranian adolescents. Endokrynol Pol. 2012;63:29–33.

  71. 71.

    Bikle D, Bouillon R, Thadhani R, Schoenmakers I. Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status? J Steroid Biochem Mol Biol. 2017;173:105–16. https://doi.org/10.1016/j.jsbmb.2017.01.007.

  72. 72.

    Yu C, Xue H, Wang L, Chen Q, Chen X, Zhang Y, et al. Serum bioavailable and free 25-Hydroxyvitamin D levels, but not its total level, are associated with the risk of mortality in patients with coronary artery disease. Circ Res. 2018;123:996–1007.

Download references

Acknowledgements

We thank Xiaomin Lin and Baoni Zeng for their help in DNA extracting and genotyping experiments.

Funding

The study was supported in part by the Healthcare Research Projects (SZGW2017010, SZGW2017015, and 201506071) and the Sanming Project of Medicine (SZSM201611017) in Shenzhen, China.

Availability of data and materials

The datasets used and analyzed during the current study available from the corresponding author on reasonable request.

Author information

J-CZ and X-LL designed the study, prepared the manuscript, and had primary responsibility for final content. J-CZ and YZ designed and established the genotyping methods. YZ, XL, XZ, YX, and JM performed the laboratory work. CG, XZ, JS JX, and SS conducted the questionnaire survey. J-CZ, DL, and XC analyzed the data. SS, CH, and X-LX organized the participants. All authors read and approved the final manuscript.

Correspondence to Ji-Chang Zhou or Xiao-Li Liu.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethic Committee of Shenzhen Centre of Chronic Disease Control, and all the subjects consented to participate the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Table S1. Plasma concentration of vitamin D binding protein at its different genotypes. Table S2. Metabolic parameters regarding glucose and lipids in male subjects grouped by the genotypes of vitamin D binding protein gene. Table S3. Partial correlation analysis on 25OHD and interested variants. Figure S1. Typical genotyping graph of 6 genotypes in vitamin D binding protein gene analyzed by molecular beacon probe-based qPCR method. (DOCX 108 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Vitamin D binding protein
  • Single nucleotide polymorphism
  • Circulating 25-hydroxyvitamin D
  • Glucose
  • Lipids
  • Han Chinese